|
Originally published In Press as doi:10.1074/jbc.M910290199 on July 5, 2000
J. Biol. Chem., Vol. 275, Issue 38, 29331-29337, September 22, 2000
Interleukin-15 Induces Rapid Tyrosine Phosphorylation of STAT6
and the Expression of Interleukin-4 in Mouse Mast Cells*
Akio
Masuda ,
Tetsuya
Matsuguchi§¶,
Kenichi
Yamaki ,
Tetsuo
Hayakawa ,
Masato
Kubo ,
William J.
LaRochelle**, and
Yasunobu
Yoshikai§
From the Second Department of Internal Medicine,
§ Laboratory of Host Defense and Germfree Life, Research
Institute for Disease Mechanism and Control, Nagoya University
School of Medicine, Nagoya 466-8550, Japan, Division of
Immunobiology, Research Institute for Biological Sciences, Science
University of Tokyo, Tokyo 278-0022, Japan, and ** Laboratory of
Cellular and Molecular Biology, NCI, National Institutes of Health,
Bethesda, Maryland 20892
Received for publication, December 27, 1999, and in revised form, June 7, 2000
 |
ABSTRACT |
Interleukin (IL)-4 plays an important role in the
differentiation of naive T helper (Th) cells into Th2. Mast cells can
produce a significant amount of IL-4 and have been proposed to play a major role in the induction of Th2 responses. Recently, it has been
reported that mast cells have a distinct IL-15 receptor system different from that of T or natural killer cells. In the present study, we demonstrated that IL-15 induced IL-4 production from a mouse
mast cell line, MC/9, and bone marrow-derived mast cells. IL-4 mRNA
expression was increased by IL-15, suggesting that IL-15 promotes IL-4
expression at the transcriptional level. In these mast cells, signal
transducer and activator of transcription (STAT) 6 were rapidly
tyrosine-phosphorylated in response to IL-15. In MC/9 cells, the
expression of a C-terminally truncated dominant negative form of STAT6
significantly suppressed the IL-4 mRNA up-regulation by IL-15,
suggesting that STAT6 activation is essential for the
IL-15-mediated IL-4 production. Additionally, tyrosine phosphorylation of Tyk2 was rapidly increased by IL-15 treatment in this cell line. Altogether, our results suggest that IL-15 plays an
important role in stimulating early IL-4 production in mast cells that
may be responsible for the initiation of Th2 response.
 |
INTRODUCTION |
Interleukin (IL)1-4 is a
multifunctional cytokine that plays important roles in the protection
against extracellular parasites, the pathogenesis of allergic diseases,
and the suppression of cell-mediated immune responses by shutting down
the synthesis and effects of interferon- (1-4). T cells of the T
helper 2 (Th2) phenotype, which first require the presence of IL-4 for their own development, produce this cytokine by themselves along with
IL-5, IL-6, and IL-10 (6-8), cytokines that are responsible for
humoral immunity. Although it has been postulated that naive CD4+ T cells can differentiate along the Th2 pathway
through the production of small amounts of autocrine IL-4, it is
generally conceived that bystander cells producing IL-4 also have a
significant effect on the initiation and amplification of the Th2
response. A number of different cell types are known to be responsible
for such early IL-4 production (5). Mast cells, widely distributed
through vascularized tissues, are able to produce a significant amount of IL-4 as well as a variety of other cytokines (9) and have been
proposed to play a major role in the generation of Th2 responses (10).
Thus, it is of great interest to elucidate the molecular mechanisms
controlling the IL-4 production in mast cells.
The Janus kinase (JAK)-signal transducer and activator of transcription
(STAT) pathway is an important cytokine-induced signal transduction
pathway that directly transfers signals from the cell surface cytokine
receptor to the nucleus (11-13). Among STAT proteins, STAT6 was first
isolated as a protein tyrosine-phosphorylated in response to IL-4
stimulation (14). STAT6 has been demonstrated to play a critical role
in regulating the Th2 response based on the analyses of STAT6-deficient
mouse models (15, 16). Recently, it has also been shown that STAT6 is
activated by IL-13 that shares many biological properties with IL-4
(17).
IL-15 is a member of the cytokines that have a T cell growth promoting
activity (18, 19). Many functional properties of IL-15 in T and NK
cells are shared by IL-2 (20) probably because the receptor complexes
for IL-15 and IL-2 share two signal-transducing subunits, IL-2 receptor
(R) and c chains, in these cell types (18, 21). In contrast, it
has recently been reported that IL-15 uses a distinct receptor system
in mast cells (22). Although mast cells do not respond to IL-2 because
of the lack of IL-2R expression, they proliferate in response to
IL-15. IL-15 seems to work on mast cells through a novel 60-65-kDa
IL-15R molecule, IL-15RX (19). However, the physiological roles of
IL-15 in mast cell functions have remained largely unknown.
In the present study, we have demonstrated that IL-15 induces IL-4
production from a mouse mast cell line, MC/9 and bone marrow-derived mast cells (BMMCs). IL-4 mRNA expression is induced by IL-15, suggesting that IL-15 promotes IL-4 production at the transcriptional level. Surprisingly, STAT6, but not STAT1, -3, or -5, is rapidly tyrosine-phosphorylated in response to IL-15. In MC/9 cells, expression of a C-terminally truncated dominant negative form of STAT6
significantly suppressed IL-4 gene expression induced by IL-15,
indicating that the activation of STAT6 is involved in the
IL-15-mediated IL-4 production. Furthermore, Tyk2 was suggested to be
responsible for the IL-15-mediated STAT6 tyrosine phosphorylation,
because Tyk2 but not Jak1, Jak2, or Jak3 was rapidly
tyrosine-phosphorylated by IL-15 treatment in this cell line.
Altogether, our results suggest that IL-15 may play an important role
in the initiation of Th2 response by stimulating IL-4 expression in
mast cells.
 |
MATERIALS AND METHODS |
Reagents and Antibodies--
Recombinant human IL-15 and mouse
IL-3 were purchased from Peprotech Corp. (Seattle, WA). RPMI 1640 medium was from Life Technologies, Inc. Fetal calf serum (FCS)
was purchased from Sigma.
The anti-IL-4 neutralizing antibody (rat IgG1, 11B11) was purchased
from PharMingen. The antiphosphotyrosine monoclonal antibody (4G10) and
the polyclonal anti-Jak2 antibody were obtained from Upstate
Biotechnology Inc. (Lake Placid, NY). The antiphospho-c-Jun N terminus
kinase and the antiphosphoextracellular signal-regulated kinase
monoclonal antibodies were obtained from New England Biolabs (Beverly,
MA). The anti-Jak1 polyclonal antibody, the anti-JAK3 monoclonal
antibody, the polyclonal antibodies against STAT5b (which recognizes
both STAT5a and STAT5b of mice), STAT3, and two polyclonal STAT6
antibodies raised against the C-terminal domain (amino acids 805-823)
or the DNA binding domain (amino acid 280-480) of STAT6 were purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). The anti-Tyk2
monoclonal antibody was obtained from Transduction Laboratories
(Lexington, KY). The rat monoclonal anti-mouse IL-2R and c
antibodies were purchased from PharMingen (San Diego, CA). The
phycoerythrin-conjugated goat anti-rat IgG was purchased from CALTAG
Laboratories (Burlingame, CA). The mouse monoclonal antidinitrophenyl
(DNP) antibody and the DNP-human serum albumin were purchased from Sigma.
Cell Lines--
All cell lines were grown in tissue culture
flasks at 37 °C in 5% CO2, 95% air and passaged every
two or three days to maintain logarithmic growth. The MC/9 mouse mast
cell line was obtained from the American Type Culture Collection
(Rockville, MD). The cells were cultured in RPMI 1640 containing 10%
FCS, 20 µM 2-mercaptoethanol, 10%
Walter and Eliza Hall
Institute (WEHI)-3-conditioned medium as a source
for IL-3, and 10% mouse-spleen-conditioned medium with concanavalin A. BMMCs were derived from femoral bone marrow cells of 6-week-old
Balb/c mice. After 3 weeks of culture with 10%
WEHI-3-conditioned medium, the cells were harvested for the experiments
and consisted of more than 98% mast cells assessed by toluidine blue staining.
For all experiments described here, cells were washed twice with
serum-free medium (RPMI 1640 containing 1% bovine serum albumin, 20 µM 2-mercaptoethanol) and incubated in the serum-free
medium before cytokine stimulation. Cytokine concentrations used for the stimulation experiments were as follows: 10 ng/ml IL-3, 10 ng/ml
IL-15, 10 ng/ml IL-3 plus IL-15 unless otherwise indicated.
Reverse Transcriptase PCR Analysis--
MC/9 cells were
incubated for 6 h at 37 °C in serum-free medium and stimulated
under various conditions. Total cellular RNA was isolated using
TrizolTM reagent (Life Technologies, Inc.) according to the
manufacturer's instructions. Total RNA (2 µg) was
reverse-transcribed using SuperScriptTM (Life Technologies,
Inc.) and 20 pmol of random primer (Life Technologies, Inc.) in 20 µl
of reaction buffer, according to the manufacturer's instructions.
Synthesized first-strand of cDNA was amplified by means of PCR
using specific sense and antisense primers (20 pmol each) with 1.25 unit of recombinant Taq (Takara Shuzou, Osaka Japan)
in a total volume of a 50-µl reaction buffer consisting of 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 0.01% gelatin, and 0.2 µM dNTP. The amplification procedure performed in a
temperature controller was as follows: after an initial denaturation step at 95 °C for 5 min, 30 cycles were performed at 95 °C for 1 min followed by 54 °C for 1 min, and 72 °C for 1 min. 5 µl of each PCR product was run on a 2% agarose gel (Life Technologies, Inc.)
for UV visualization.
Primer sequences were as follows: IL-4 sense,
5'-CGAAGAACACCACAGAGACTGAGCT-3'; antisense,
5'-GACTCATTCATGGTGCAGCTTATCG-3'; IL-13 sense,
5'-ATGAGTCTGCAGTATCCCG-3'; antisense, 5'-CCGTGGCAGACAGGAGTGTT-3'; tumor
necrosis factor- , 5'-GGCAGGTCTACTTTGGAGTCATTGC-3'; antisense, 5'-ACATTCGAGGCTCCAGTGAATTCGG-3'.
Nothern Blot Analysis--
Cells were incubated for 6 h at
37 °C in serum-free medium and stimulated under various conditions.
Total cellular RNA was isolated as described above. 20-µg aliquots of
the total RNAs were fractionated on a 1% agarose gel containing 20 mM MOPS, 5 mM sodium acetate, 1 mM
EDTA (pH 7.0), and 6% (v/v) formaldehyde and transferred to a nylon
membrane. After UV-cross-linking, membranes were soaked in
prehybridization solution (6× SSC, 5× Denhardt's reagent, 0.5% SDS,
100 mg/ml denatured salmon sperm DNA, and 50% formamide) for 3 h
at 65 °C followed by incubation with 32P-labeled probe
in hybridization solution (6× SSC, 0.5% SDS, 100 mg/ml denatured
salmon sperm DNA, and 50% formamide) for 14 h at 65 °C. The
membranes were washed in 2× SSC, 0.1% SDS for 10 min twice at room
temperature, in 0.1× SSC, 0.1% SDS for 10 min twice at 50 °C and
were exposed to Fuji RX-U films (Fuji Film, Tokyo, Japan). cDNA
fragments of the coding regions of mouse IL-4 and -actin were used
as specific probes.
Transfection and Luciferase Assay--
The luciferase reporter
vector containing the IL-4 promoter (pIL-4 ( 766) Lu) was described
previously (23). MC/9 cells were transiently transfected with 3 µg of
pIL-4 ( 766) Lu and 0.5 µg of pRL/SV40 (an internal control) by
1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethylammonium bromide-C Reagent (Life Technologies, Inc.) according to the
manufacturer's instructions. 24 h after the transfection, the
transfected cells were stimulated with IL-15 (10 ng/ml) or left
untreated. After a 12-h incubation with IL-15, cells were lysed, and
the luciferase activity was measured by using the dual-luciferase
reporter assay system (Toyo Ink Co., Tokyo, Japan) according to the
manufacturer's instructions. The data were presented as the mean ± S.D. of triplicate samples.
Immunoprecipitation and Western Blotting Analysis--
Cells
were incubated for 6 h at 37 °C in serum-free medium and
stimulated under various conditions; they were lysed in ice-cold lysis
buffer (50 mM Hepes, pH 7.0, 150 mM NaCl, 10%
glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA, 100 mM NaF, 10 mM
NaPPi, 1 mM Na3VO4, 1 mM phenylmethanesulfonyl fluoride with aprotinin and
leupeptin at 10 µg/ml) and incubated on ice for 20 min. Samples were
centrifuged (15000 rpm, 5 min), and the supernatants were stored at
80 °C for further experiments.
For immunoprecipitation, 100 µl of cell lysate (from 1 × 107 cells) was rotated with a primary antibody overnight at
4 °C, added with 20 µl of protein A-Sepharose bead slurry (1:1,
beads:lysis buffer), and incubated further for 1 h at 4 °C. In
all cases, beads were washed three times with lysis buffer and boiled
in the loading buffer before electrophoresis.
Lysates or immunoprecipitates were analyzed on a 7.5, 10, or 12%
SDS-polyacrylamide gel, and the proteins were transferred to Immobilon
polyvinylidene difluoride membranes (Millipore, Bedford, MA). Membranes
were blocked with 1% bovine serum albumin in Tris-buffered saline
containing 0.05% Tween-20 (TBST) for 1 h, and Western blot analysis was performed as described previously (24) followed by
detection using enhanced chemiluminescence system (Amersham Pharmacia
Biotech) according to the manufacturer's instructions.
IL-4 ELISA--
MC/9 cells were sensitized by incubating for
2 h with 1 µg/ml anti-DNP IgE in RPMI 1640 containing 10% FCS,
washed, and incubated (2 × 106 cells/ml) with 50 ng/ml DNP-human serum albumin, in the presence of 10 ng/ml IL-15 or
not. The cell-free culture supernatants were collected after 48 h
of culture. The IL-4 concentrations in the culture supernatants were
assayed by ELISA using a mouse IL-4 ELISA system (Genzyme, Minneapolis,
MN) according to the manufacturer's instructions.
Flow Cytometry--
MC/9 cells were stained with anti-mouse
IL-2R , c chain antibody, or isotype-matched control rat IgG,
followed by the phycoerythrin-conjugated goat anti-rat IgG. After
washing, the cells were resuspended and analyzed using a FACSCalibur
flow cytometer (Becton Dickinson, Mountain View, CA).
Generation of Stable Transfectants--
The dominant negative
STAT6 expression plasmid was generated by cloning the DNA encoding
C-terminally truncated human STAT6 (containing amino acid 1-662) into
pCEV29 vector. MC/9 cells were transfected with an electroporator using
20 µg of plasmid DNA at the condition of 800 microfarad and 300 V. Transfectants were selected with G418 (1 mg/ml). Resistant clones were
screened for the right sized protein expression by Western blotting
using an anti-STAT6 antibody (directed against amino acid 280-480).
Statistical Analysis--
The statistical significance of the
data was determined by the Student's t test. A p
value of less than 0.05 was taken as significant.
 |
RESULTS |
Surface Expression of IL2R Chains on MC/9 Cells--
It is
generally accepted that the IL-15 receptor is composed of three
subunits, two of which (IL-2R and c) are shared by IL-2 (20, 21).
However, in a previous report, it has been reported that the IL-2R
chain is not expressed on mast cells, and IL-15 seems to utilize a
novel receptor, IL-15RX (22). To examine the surface expression of
IL-2R and c chains on MC/9, a well established mouse mast cell
line used in the experiments, flow cytometry analyses were performed
using specific monoclonal antibodies (mAb). As shown in Fig.
1, there was no detectable surface
expression of IL-2R on MC/9 cells, although they expressed the c
chain as previously reported (22). To confirm that the expression
profile is not specific to this cell line, we also examined mouse BMMCs
for IL-2R expression. They also expressed c but not IL-2R on the
surface as reported earlier (22) (data not shown).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 1.
The surface expression of IL2R chains on MC/9
cells. MC/9 cells were stained with rat anti-mouse
IL-2R , c chain, or isotype-matched
control rat IgG followed by an fluorescein isothiocyanate-conjugated
goat anti-rat IgG. After washing, the cells were resuspended and
analyzed by flow cytometry. White areas denote staining with
an isotype control antibody, whereas black areas indicate
anti-IL2R antibody staining.
|
|
Mast Cells Increased IL-4 mRNA Expression in Response to IL-15
Stimulation--
Although it has been reported that IL-15 supports the
growth of mast cells (22), other effects of IL-15 on mast cells have not been fully explored. As mast cells are able to produce a variety of
cytokines including IL-3, IL-4, IL-5, IL-6, IL-10, IL-13, tumor necrosis factor- , and granulocyte-macrophage colony-stimulating factor in response to various stimulations (25-29), we sought to examine whether exogenous IL-15 affects cytokine mRNA expression in
MC/9 cells. Cells were incubated with IL-15 for 0, 1, 2, or 4 h
and harvested for RNA preparation. Total RNAs from these cells were
reverse-transcribed and then used for PCR amplification with pairs of
specific primers for IL-4, IL-13, and tumor necrosis factor- .
Reverse transcriptase-PCR products for -actin were measured to
verify the integrity of the RNA. As shown in Fig. 2A, factor-derived MC/9 cells
expressed a low level of mRNA for IL-4. IL-4 mRNA was
significantly increased after 2- and 4-h stimulations by IL-15. In
contrast, either IL-13 or tumor necrosis factor- mRNA was not
altered by the IL-15 stimulation. To know the concentration of IL-15
needed to induce IL-4 mRNA, MC/9 cells were stimulated with various
concentration of IL-15 for 4 h and harvested for Northern blot
analysis. As shown in Fig. 2B, IL-15 induced a weak IL-4
mRNA increase at 100 pg/ml, whereas 1000 and 10,000 pg/ml IL-15
induced more evident increase. IL-4 mRNA was also significantly increased by IL-15 treatment in BMMCs (Fig. 2C).

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 2.
A, cytokine mRNA expression in MC/9
cells stimulated by IL-15. MC/9 cells were incubated for 6 h at
37 °C in serum-free medium and stimulated by IL-15 (10 ng/ml) for
the indicated times. Total RNAs (2 µg) from MC/9 cells were
reverse-transcribed and amplified by PCR as described under
"Materials and Methods." Products using primers for each cytokine
were resolved on 2% agarose gels and visualized by staining with
ethidium bromide. The length of each product matched that predicted
from the sequence data. TNF, tumor necrosis factor.
B, dose response of IL-4 mRNA expression induced by
IL-15 in MC/9 cells. MC/9 cells were incubated for 6 h at 37 °C
in serum-free medium and stimulated by 0, 10, 100, 1000, or 10,000 pg/ml IL-15 for 4 h. Total RNA (20 µg) from MC/9 cells was used
in Northern blot analysis. The filter was hybridized first with a
IL-4-specific probe and then stripped and reprobed for -actin.
C, IL-4 mRNA expression induced by IL-15 in BMMCs. BMMCs
were incubated for 6 h at 37 °C in serum-free medium and
stimulated by IL-15 (10 ng/ml) for 4 h. Total RNA (20 µg) from
BMMCs was used in Northern blot analysis. The filter was hybridized
first with a IL-4-specific probe and then stripped and reprobed for
-actin. D, transcriptional activation of a luciferase
reporter construct driven by the IL-4 promoter in response to IL-15.
MC/9 cells cotransfected with pIL-4 ( 766) Lu and pRL/SV40 were
treated with IL-15 (10 ng/ml) for 12 h or left untreated. Units of
luciferase activity were normalized based on values of pRL/SV40
activity for transfection activ ity. The experiment was done in triplicate. The error bars
represent S.D. values. * denotes significantly different values
compared with the unstimulated sample (p < 0.05).
E, IL-4 mRNA expression under the IL-4 depletion
condition in MC/9 cells stimulated by IL-15. MC/9 cells were pretreated
with anti-IL-4 antibody (10 µg/ml) or not for 30 min and incubated
with IL-15 (10 ng/ml) for 6 h.
|
|
We next examined IL-4 promoter activity in IL-15-treated mast cells.
MC/9 cells were transiently transfected with a luciferase reporter
construct that contained an IL-4 promoter region (IL-4 ( 760) Lu), and
luciferase activity was measured after a 12-h stimulation by IL-15. As
shown Fig. 2D, IL-15 significantly increased the promoter
activity of the IL-4 gene.
To confirm whether the increase of IL-4 induced by IL-15 stimulation
might contribute to the increase of IL-4 itself, we utilize a
neutralizing antibody against mouse IL-4. MC/9 cells were incubated with IL-15 in the presence of the anti-IL-4 mAb for 6 h, and
reverse transcriptase-PCR analysis was performed. The effectiveness of the neutralization was confirmed by the observation that the same concentration of this antibody could abrogate the IL-4-induced tyrosine
phosphorylation of STAT6 (data not shown). As shown in Fig.
2E, the existence of Anti IL-4 mAb did not affect the
increase of IL-4 mRNA.
Mast Cells Secreted IL-4 in Culture Supernatants in Response to
IL-15--
To determine whether IL-15 stimulates IL-4 protein
secretion from mast cells, we measured IL-4 concentration in the
culture supernatants of mast cells incubated with IL-15. BMMCs were
incubated with IL-15 or not for 24 h. As shown in Fig.
3A, IL-15, when added to the
culture, significantly increased the IL-4 concentration in the culture
supernatant. MC/9 cells that we used produced a very small amount of
IL-4 even when stimulated by ionomycin (data not shown), which is a
strong inducer of IL-4 production (27), and they hardly produced IL-4
in the presence of IL-15 (data not shown). Thus, we used IL-15 in
combination with antigen/antigen-specific IgE stimulation that is a
potent inducer of IL-4 from mast cells (27). As shown in Fig.
3B, MC/9 cells secreted a small amount of IL-4 in the
presence of DNP/DNP-specific IgE. IL-15, when added to the culture,
increased the IL-4 concentration. These data provide evidence that
IL-15 is a potent inducer of IL-4 production from mast cells.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 3.
IL-4 secretion from mast cells stimulated
with IL-15. A, BMMCs (2 × 106 cells)
were incubated in RPMI + 10% FCS with 10 ng/ml IL-15 or not. The
cell-free culture supernatants were collected after 24 h of
culture. B, MC/9 cells (5 × 106 cells)
were incubated in RPMI + 10% FCS with 1 mg/ml anti-DNP-human serum
albumin IgE mAb for 2 h. Cells were washed twice and resuspended
in medium with 100 ng/ml DNP-human serum albumin and IL-15 (10 ng/ml)
or not. The cell-free culture supernatants were collected after 48 h of culture. The IL-4 contents in the culture supernatants were
assayed by ELISA using a mouse IL-4 ELISA system. The experiments were
done in triplicate. The error bars represent S.D. values. **,
p < 0.01.
|
|
IL-15 Induced Rapid STAT6 Tyrosine Phosphorylation in Mast
Cells--
The JAK/STAT pathway is an important cytokine-induced
signal transduction pathway that directly transfers signals from cell surface cytokine receptor to the nucleus. As it had been known that
STAT6 played an important role in the regulation of IL-4 gene
expression by IL-4 in helper T cells (30), we sought to examine STAT6
tyrosine phosphorylation after IL-15 stimulation in MC/9 cells.
Factor-deprived MC/9 cells were stimulated with various concentration
of IL-15 for 30 min before lysis. STAT6 was immunoprecipitated from the
cell lysates, and subsequent Western blotting analysis was performed
using an antiphosphotyrosine antibody. To compare the degree of
tyrosine phosphorylation, MC/9 cells were also stimulated for 30 min
with IL-3, a major growth factor for mast cells. As shown in Fig.
4A, IL-15 clearly induced
STAT6 tyrosine phosphorylation within 30 min. At 100 or 1000 pg/ml, IL-15 induced moderate STAT6 tyrosine phosphorylation, whereas 10,000 pg/ml IL-15 induced it more evidently. In the time course analysis, the
maximum induction of STAT6 tyrosine phosphorylation was found to occur
between 15 and 30 min of IL-15 stimulation (Fig. 4B).
Although it has been reported that IL-15 stimulates STAT5 tyrosine
phosphorylation in another mast cell line (PT-18) (22), we could not
detect any STAT5 tyrosine phosphorylation in MC/9 cells after IL-15
stimulation (Fig. 4C). Additionally, IL-15 did not induce
any detectable tyrosine phosphorylation of other members of STAT,
STAT1, STAT3, or STAT4 (data not shown). Additionally, IL-15 also
stimulated STAT6 tyrosine phosphorylation in BMMCs (Fig.
4D). To confirm STAT6 tyrosine phosphorylation that we
observed was directly regulated by IL-15 and not because of the
autocrine effect by IL-4, we examined STAT6 tyrosine phosphorylation under an IL-4 depletion condition. As shown Fig. 4E, IL-4
depletion from the culture supernatant by the neutralizing anti-IL-4
mAb did not affect the STAT6 tyrosine phosphorylation by IL-15
stimulation (Fig. 4E).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 4.
Tyrosine phosphorylation of STATs in mast
cells stimulated with IL-15. A, dose response of STAT6
tyrosine phosphorylation in MC/9 cells. MC/9 cells were stimulated with
0, 10, 100, 1000, or 10,000 pg/ml IL-15 for 30 min. STAT6
immunoprecipitates (IP) were blotted with indicated
antibodies. B, time course of STAT6 tyrosine phosphorylation
by IL-15 in MC/9 cells. MC/9 cells were stimulated with IL-15 (10 ng/ml) for 0, 15, 30, and 60 min or IL-3 (10 ng/ml) for 30 min.
C, cytokine-mediated STAT5 tyrosine phosphorylation in MC/9
cells. MC/9 cells were stimulated with IL-15 (10 ng/ml) for 0, 15, 30, and 60 min or IL-3 (10 ng/ml) for 30 min. STAT5 immunoprecipitates were
blotted with indicated antibodies. D, tyrosine
phosphorylation of STAT6 in BMMCs stimulated with IL-15. BMMCs were
stimulated with IL-15 (10 ng/ml) for 15 min. STAT6 immunoprecipitates
were blotted with indicated antibodies. E, tyrosine
phosphorylation of STAT6 under IL-4 deprivation condition in MC/9 cells
stimulated with IL-15. MC/9 cells were pretreated with anti-IL-4
antibody (10 µg/ml) or not for 30 min followed by a 30-min IL-15
stimulation (10 ng/ml).
|
|
Expression of a Dominant Negative STAT6 Mutant Inhibited
IL15-mediated IL-4 mRNA Expression--
To examine if the
activation of STAT6 was responsible for the IL-4 production in response
to IL-15, we transfected an expression plasmid encoding a C-terminally
truncated form of STAT6 in MC/9 cells. This mutant lacks the C-terminal
transactivation domain. Three clones expressing this short form of
STAT6 were isolated for analyses. The Western blotting result of a
typical clone was shown in Fig.
5A. To examine if this STAT6
mutant worked in a dominant negative fashion, we stimulated a positive
clone with IL-4 or IL-15 and analyzed the tyrosine phosphorylation of
the endogenous STAT6. As shown in Fig. 5B, both IL-4- and
IL-15-mediated STAT6 tyrosine phosphorylations were significantly
inhibited in this clone, suggesting that this C-terminally truncated
STAT6 mutant worked in a dominant negative fashion. When IL-15-induced IL-4 mRNA expression was examined by the semiquantitative reverse transcriptase-PCR, it was significantly decreased in these cells compared with that of the parental MC/9 cells (Fig. 5C).
These results strongly indicated that STAT6 activation is essential for
the IL-4 production mediated by IL-15.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 5.
Effect of a dominant negative STAT6 on the
IL-15-mediated expression of IL-4 mRNA. A,
expression of the C-terminally truncated form of STAT6 in MC/9 cells.
Western blot analysis was performed with whole cell extracts from the
parental and a G418-resistant clones. The membrane was probed with an
antibody generated against the DNA binding domain of STAT6.
B, IL-4- and IL-15-induced tyrosine phosphorylation of STAT6
in MC/9 cells expressing the C-terminal truncated form of STAT6. Cells
were stimulated with IL-4 (10 ng/ml) or IL-15 (10 ng/ml) for 30 min.
Each lane represents STAT6 immunoprecipitated (IP) from
3 × 106 cell lysate. The membrane was first probed
with an antiphosphotyrosine antibody (4G10), stripped, and then
reprobed using an antibody against STAT6. C,
expression of IL-4 mRNA induced by IL-15 in dominant negative-STAT6
expressing cells. Cells were incubated for 6 h at 37 °C in
serum-free medium and stimulated with IL-15 (10 ng/ml) for the
indicated times. Total RNA (2 µg/each) was reverse-transcribed and
PCR-amplified as described.
|
|
IL-15 Induced Tyrosine Phosphorylation of Tyk2--
To study the
upstream regulators of STAT6 tyrosine phosphorylation, the activation
of JAK family kinases was examined in IL-15-stimulated MC/9 cells.
Factor-starved MC/9 cells were stimulated with 10 ng/ml of IL-15 for 0, 15, 30, and 60 min before cell lysis, and JAK kinases were
immunoprecipitated by their specific antibodies to examine the tyrosine
phosphorylation status by immunoblotting using an antiphosphotyrosine
mAb (4G10). As shown Fig. 6A,
Tyk2 was rapidly tyrosine-phosphorylated by IL-15. Although
IL-15-induced JAK2 tyrosine phosphorylation has been reported in
another mast cell line (PT-18) (22), we could not detect any tyrosine
phosphorylation of JAK2 in MC/9 cells (Fig. 6B). Also, IL-15
did not induce any detectable tyrosine phosphorylation of the other
members of JAKs, JAK1, or JAK3 (data not shown).

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 6.
Tyrosine phosphorylation of JAK kinases in
MC/9 cells following the addition of IL-15. A, tyrosine
phosphorylation of Tyk2. MC/9 cells were stimulated with IL-15 (10 ng/ml) for 0, 15, 30, and 60 min or IL-3 (10 ng/ml) for 30 min. Tyk2
was immunoprecipitated (IP) from cell lysates (from 3 × 106 cells), probed with an antiphosphotyrosine antibody
(4G10), stripped, and then reprobed using antibodies against individual
JAK kinase. B, tyrosine phosphorylation of JAK2. MC/9 cells
were stimulated as in A. Jak2 immunoprecipitates were probed
with antiphosphotyrosine and then anti-Jak2 antibody.
|
|
 |
DISCUSSION |
In this study, we have shown that IL-15 induces IL-4 production
from a mouse mast cell line, MC/9, and BMMCs. IL-4 mRNA expression is also induced by IL-15, suggesting that the induction is regulated at
the transcriptional level. We have found that Tyk2 and STAT6, but not
JAK1, -2, -3, STAT1, -3, -4, or -5, are rapidly tyrosine-phosphorylated in response to IL-15 in MC/9 cells. STAT6 is also rapidly
tyrosine-phosphorylated by IL-15 in BMMCs. Additionally, the
expression of a C-terminally truncated dominant negative form of STAT6
significantly suppressed the IL-4 mRNA up-regulation by IL-15,
suggesting that STAT6 activation is essential for the IL-15-mediated
IL-4 production.
Although the exact molecular mechanisms for the tissue-specific
expression of the IL-4 gene have not been clearly shown, IL-4 gene
expression is primarily controlled by transcriptional factors binding
to the 5'-regulatory regions of the IL-4 promoter (31). IL-4 gene
expression during Th2 cell differentiation is at least partly because
of c-maf and GATA-3, transcription factors expressed specifically in
Th2 cells (30). Additionally, other transcription factors,
nuclear factor of activation in T cells (NF-AT), NF-AT interacting protein, and activator protein-1 have also been reported to
be involved in the IL-4 gene activation (30). STAT6, first identified
as a transducer of IL-4 receptor signaling, binds both the promoter and
the silencer of the IL-4 gene (23, 32-34). Although it is still not
clear whether STAT6 directly regulates IL-4 gene transcription, the
critical role of STAT6 in Th2 cell development was demonstrated by the
targeted disruption of the STAT6 gene in mice. These mice were severely
defective in generating the Th2 type immune responses (15, 16). It has
been postulated that STAT6 may mediate the Th2-specific expression of
IL-4 through an autocrine mechanism by binding and transactivating the
IL-4 promoter in T lymphocytes (30).
It is generally accepted that bystander cells responsible for early
IL-4 production play an important role in the initiation of Th2
response of the early stage of immune response. Among these cells, mast
cells may play an essential role, as they are widely distributed
through vascularized tissues and are able to produce a large amount of
IL-4 (27). Our current data suggest that IL-15, a cytokine produced by
a wide variety of cell types including macrophage and epithelial cells
in the early phase of infectious diseases (19), may play a part in the
initiation of Th2 type immune responses by inducing IL-4 production
from mast cells.
The tyrosine phosphorylation of STAT6 by IL-15 and the suppression of
IL-15-mediated IL-4 mRNA expression by a dominant negative form of
STAT6 strongly suggest that STAT6 is essential in the process (Figs. 4
and 5). Additionally, IL-15 induced the activation of IL-4 promoter,
which contains three STAT-responsive elements (23, 33). This is not a
cell line-specific phenomenon, because mouse BMMCs also showed
increased IL-4 mRNA and STAT6 tyrosine phosphorylation in response
to IL-15 (Figs. 2C and 4D). In contrast to our
present findings, it has been reported that BMMCs from STAT6 / mice can express IL-4 comparable to those of
wild-type mast cells, and mutation of the consensus STAT6 sites does
not diminish IL-4 promoter activity (35). However, in this study, mast
cells were stimulated by ionomycin, a strong inducer of IL-4 production
from mast cells (27), and the IL-15-mediated IL-4 expression has never
been explored.
In T cells, it is still uncertain if the activated STAT6 directly
induces IL-4 production. As multimers of STAT6-corresponding elements
were inducible by IL-4 when linked to heterologous promoters and
transfected into STAT6-expressing B-cell lines (32), it seemed
reasonable to conclude that STAT6 would directly enhance IL-4
transcription in T cells. However, a recent study using STAT6-deficient Jurkat T cells has suggested that although cotransfected STAT6 strongly
enhanced transcription from the multimerized STAT6 response elements,
the human IL-4 promoter was significantly repressed under similar
conditions (33), suggesting that STAT6 might directly inhibit the IL-4
promoter function in some types of cells. In mast cells, mechanisms of
IL-4 production have not been well understood but seem to be different
from those in T cells. Another evidence for this hypothesis in addition
to our present findings is a recent report that IL-4 production by mast
cells does not require c-maf (36).
It is of note that a novel STAT6 isoform has been reported to be
present in mast cells (37). In the report, this STAT6 isoform is also
tyrosine-phosphorylated by IL-4, 65 kDa in size, and lacks reactivity
with an anti-STAT6 antibody directed toward the C terminus, suggesting
that it is a C-terminally truncated form. We sought to examine the
existence of this short form of STAT6 in the MC/9 cell line we used.
Although we utilized the same antibody used in the previous report,
which was against the middle portion of STAT6, we could not detect a
molecule around 65 kDa in MC/9 cells (data not shown). This is probably
not because of the problem with our MC/9 cells, because the same
antibody did not detect this short STAT6 isoform in mouse BMMCs (data
not shown). Currently, we consider that the different antibody batches
could cause the different Western blotting results.
Because mast cells constitutively produce a small amount of IL-4 (38)
and IL-15 induces the IL-4 secretion (Fig. 3), STAT6 tyrosine
phosphorylation that we observed might not be directly regulated by
IL-15 and may be because of the autocrine effect by IL-4. However, we
consider this possibility unlikely by the following reasons. First,
Tyk2 and STAT6 were very rapidly tyrosine-phosphorylated as early as 15 min after stimulation with IL-15. Second, IL-4 depletion from the
culture supernatant by a neutralizing anti-IL-4 mAb did not affect the
STAT6 tyrosine phosphorylation by IL-15 (Fig. 4E).
In our study, we have demonstrated that exogenous IL-15 induces IL-4
mRNA synthesis, a phenomenon that has not been reported in T cells.
Recently it has been reported that IL-15 uses a distinct receptor
system in mast cells, which does not utilize IL-2 R and is
designated as IL-15 RX (22). Therefore, it is suggested that the mast
cell-specific downstream signals from IL-15RX may play a role in the
induction of IL-4 expression.
Our current findings suggest that the IL-15-mediated IL-4 production
from mast cells may play an important part in some types of infectious
diseases. For example, IL-15 is produced early in the intracellular
parasite infections (39, 40). In a mouse model, it has been reported
that IL-15·IgG2b fusion protein accelerates and enhances Th2
type response in vivo (41). This fusion protein seems to
prolong its half-life in vivo and enhances IL-15 effects. This report is consistent with our current findings and suggests that
at least in some cases IL-15 is responsible for the initiation of Th2
type immune responses. Also epithelial cells are known to produce an
appreciable level of IL-15 following infection (42, 43). Thus, it
appears that IL-15 produced locally stimulates mast cells to secret
IL-4 and in turn serves to alert a host defense system to local
infection. In conclusion, our present data have suggested that
IL-15 may play a role in the initiation of Th2 type immune responses by
inducing IL-4 production from mast cells through its unique receptor.
 |
FOOTNOTES |
*
This work was supported by a grant from YASUDA Medical
Reserch Foundation, Yakult Bioscience Foundation Grant
JSPS-RFTF97L00703, and the Center of Excellence of the Japanese
Government.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence and reprint requests should be
addressed: Laboratory of Host Defense and Germfree Life, Research Inst. for Disease Mechanism and Control, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. Tel.: (052) 744-2447; Fax: (052) 744-2449; E-mail:
tmatsugu@med.nagoya-u.ac.jp.
Published, JBC Papers in Press, July 5, 2000, DOI 10.1074/jbc.M910290199
 |
ABBREVIATIONS |
The abbreviations used are:
IL, interleukin;
Th, T helper;
JAK, Janus kinase;
STAT, signal transducer and activation of
transcription;
BMMC, bone marrow derived mast cell;
FCS, fetal calf
serum;
DNP, dinitrophenyl;
PCR, polymerase chain reaction;
MOPS, morpholinopropane sulfonic acid;
ELISA, enzyme-linked immunosorbent
assay;
mAb, monoclonal antibody;
R, receptor.
 |
REFERENCES |
| 1.
|
Romagnani, S.
(1994)
Annu. Rev. Immunol.
12,
227-257
|
| 2.
|
Paul, W. E.
(1991)
Blood
77,
1859-1870
|
| 3.
|
Martinez, O. M.,
Gibbons, R. S.,
Garovoy, M. R.,
and Aronson, F. R.
(1990)
J. Immunol.
144,
2211-2215
|
| 4.
|
Peleman, R.,
Wu, J.,
Fargeas, C.,
and Delespesse, G.
(1989)
J. Exp. Med.
170,
1751-1756
|
| 5.
|
Keegan, A. D.,
and Paul, W. E.
(1992)
Immunol. Today
13,
63-68
|
| 6.
|
Seder, R. A.,
Paul, W. E.,
Davis, M. M.,
and Fazekas de St Groth, B.
(1992)
J. Exp. Med.
176,
1091-1098
|
| 7.
|
Hsieh, C. S.,
Heimberger, A. B.,
Gold, J. S.,
O'Garra, A.,
and Murphy, K. M.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
6065-6069
|
| 8.
|
Swain, S. L.,
Weinberg, A. D.,
and English, M.
(1990)
J. Immunol.
144,
1788-1799
|
| 9.
|
Metcalfe, D. D.,
Baram, D.,
and Mekori, Y. A.
(1997)
Physiol. Rev.
77,
1033-1079
|
| 10.
|
Coffman, R. L.,
and von der Weid, T.
(1997)
J. Exp. Med.
185,
373-375
|
| 11.
|
Darnell, J. E., Jr.,
Kerr, I. M.,
and Stark, G. R.
(1994)
Science
264,
1415-1421
|
| 12.
|
Ihle, J. N.
(1995)
Nature
377,
591-594
|
| 13.
|
Taniguchi, T.
(1995)
Science
268,
251-255
|
| 14.
|
Hou, J.,
Schindler, U.,
Henzel, W. J.,
Ho, T. C.,
Brasseur, M.,
and McKnight, S. L.
(1994)
Science
265,
1701-1706
|
| 15.
|
Takeda, K.,
Tanaka, T.,
Shi, W.,
Matsumoto, M.,
Minami, M.,
Kashiwamura, S.,
Nakanishi, K.,
Yoshida, N.,
Kishimoto, T.,
and Akira, S.
(1996)
Nature
380,
627-630
|
| 16.
|
Kaplan, M. H.,
Schindler, U.,
Smiley, S. T.,
and Grusby, M. J.
(1996)
Immunity
4,
313-319
|
| 17.
|
Zurawski, G.,
and de Vries, J. E.
(1994)
Immunol. Today
15,
19-26
|
| 18.
|
Bamford, R. N.,
Grant, A. J.,
Burton, J. D.,
Peters, C.,
Kurys, G.,
Goldman, C. K.,
Brennan, J.,
Roessler, E.,
and Waldmann, T. A.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
4940-4944
|
| 19.
|
Waldmann, T. A.,
and Tagaya, Y.
(1999)
Annu. Rev. Immunol
17,
19-49
|
| 20.
|
Grabstein, K. H.,
Eisenman, J.,
Shanebeck, K.,
Rauch, C.,
Srinivasan, S.,
Fung, V.,
Beers, C.,
Richardson, J.,
Schoenborn, M. A.,
and Ahdieh, M.
(1994)
Science
264,
965-968
|
| 21.
|
Giri, J. G.,
Ahdieh, M.,
Eisenman, J.,
Shanebeck, K.,
Grabstein, K.,
Kumaki, S.,
Namen, A.,
Park, L. S.,
Cosman, D.,
and Anderson, D.
(1994)
EMBO J.
13,
2822-2830
|
| 22.
|
Tagaya, Y.,
Burton, J. D.,
Miyamoto, Y.,
and Waldmann, T. A.
(1996)
EMBO J.
15,
4928-4939
|
| 23.
|
Kubo, M.,
Ransom, J.,
Webb, D.,
Hashimoto, Y.,
Tada, T.,
and Nakayama, T.
(1997)
EMBO J.
16,
4007-4020
|
| 24.
|
Matsuguchi, T.,
Zhao, Y.,
Lilly, M. B.,
and Kraft, A. S.
(1997)
J. Biol. Chem.
272,
17450-17459
|
| 25.
|
Galli, S. J.,
Gordon, J. R.,
and Wershil, B. K.
(1991)
Curr. Opin. Immunol.
3,
865-872
|
| 26.
|
Galli, S. J.
(1993)
N. Engl. J. Med.
328,
257-265
|
| 27.
|
Plaut, M.,
Pierce, J. H.,
Watson, C. J.,
Hanley-Hyde, J.,
Nordan, R. P.,
and Paul, W. E.
(1989)
Nature
339,
64-67
|
| 28.
|
Wodnar-Filipowicz, A.,
Heusser, C. H.,
and Moroni, C.
(1989)
Nature
339,
150-152
|
| 29.
|
Burd, P. R.,
Thompson, W. C.,
Max, E. E.,
and Mills, F. C.
(1995)
J. Exp. Med.
181,
1373-1380
|
| 30.
|
Szabo, S. J.,
Glimcher, L. H.,
and Ho, I. C.
(1997)
Curr. Opin. Immunol.
9,
776-781
|
| 31.
|
Todd, M. D.,
Grusby, M. J.,
Lederer, J. A.,
Lacy, E.,
Lichtman, A. H.,
and Glimcher, L. H.
(1993)
J. Exp. Med.
177,
1663-1674
|
| 32.
|
Lederer, J. A.,
Perez, V. L.,
DesRoches, L.,
Kim, S. M.,
Abbas, A. K.,
and Lichtman, A. H.
(1996)
J. Exp. Med.
184,
397-406
|
| 33.
|
Georas, S. N.,
Cumberland, J. E.,
Burke, T. F.,
Chen, R.,
Schindler, U.,
and Casolaro, V.
(1998)
Blood
92,
4529-4538
|
| 34.
|
Huang, H.,
Hu-Li, J.,
Chen, H.,
Ben-Sasson, S. Z.,
and Paul, W. E.
(1997)
J. Immunol.
159,
3731-3738
|
| 35.
|
Sherman, M. A.,
Secor, V. H.,
Lee, S. K.,
Lopez, R. D.,
and Brown, M. A.
(1999)
Eur. J. Immunol.
29,
1235-1242
|
| 36.
|
Sherman, M. A.,
Nachman, T. Y.,
and Brown, M. A.
(1999)
J. Immunol.
163,
1733-1736
|
| 37.
|
Sherman, M. A.,
Secor, V. H.,
and Brown, M. A.
(1999)
J. Immunol.
162,
2703-2708
|
| 38.
|
Yoshikawa, H.,
Nakajima, Y.,
and Tasaka, K.
(1999)
J. Immunol.
162,
6162-6170
|
| 39.
|
Doherty, T. M.,
Seder, R. A.,
and Sher, A.
(1996)
J. Immunol.
156,
735-741
|
| 40.
|
Nishimura, H.,
Hiromatsu, K.,
Kobayashi, N.,
Grabstein, K. H.,
Paxton, R.,
Sugamura, K.,
Bluestone, J. A.,
and Yoshikai, Y.
(1996)
J. Immunol.
156,
663-669
|
| 41.
|
Ruckert, R.,
Herz, U.,
Paus, R.,
Ungureanu, D.,
Pohl, T.,
Renz, H.,
and Bulfone-Paus, S.
(1998)
Eur. J. Immunol.
28,
3312-3320
|
| 42.
|
Hirose, K.,
Suzuki, H.,
Nishimura, H.,
Mitani, A.,
Washizu, J.,
Matsuguchi, T.,
and Yoshikai, Y.
(1998)
Infect. Immun.
66,
5677-5683
|
| 43.
|
Sakai, T.,
Kusugami, K.,
Nishimura, H.,
Ando, T.,
Yamaguchi, T.,
Ohsuga, M.,
Ina, K.,
Enomoto, A.,
Kimura, Y.,
and Yoshikai, Y.
(1998)
Gastroenterology
114,
1237-1243
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. P. Carroll, V. Paunovic, and M. Gadina
Signalling, inflammation and arthritis: Crossed signals: the role of interleukin-15 and -18 in autoimmunity
Rheumatology,
September 1, 2008;
47(9):
1269 - 1277.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Wang, J. W. Holland, A. Carrington, J. Zou, and C. J. Secombes
Molecular and Functional Characterization of IL-15 in Rainbow Trout Oncorhynchus mykiss: A Potent Inducer of IFN-{gamma} Expression in Spleen Leukocytes
J. Immunol.,
August 1, 2007;
179(3):
1475 - 1488.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Masuda, K. Hashimoto, T. Yokoi, T. Doi, T. Kodama, H. Kume, K. Ohno, and T. Matsuguchi
Essential Role of GATA Transcriptional Factors in the Activation of Mast Cells
J. Immunol.,
January 1, 2007;
178(1):
360 - 368.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Giron-Michel, M. Giuliani, M. Fogli, D. Brouty-Boye, S. Ferrini, F. Baychelier, P. Eid, C. Lebousse-Kerdiles, D. Durali, R. Biassoni, et al.
Membrane-bound and soluble IL-15/IL-15R{alpha} complexes display differential signaling and functions on human hematopoietic progenitors
Blood,
October 1, 2005;
106(7):
2302 - 2310.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. C. Fish, D. D. Donaldson, S. J. Goldman, C. M. M. Williams, and M. T. Kasaian
IgE Generation and Mast Cell Effector Function in Mice Deficient in IL-4 and IL-13
J. Immunol.,
June 15, 2005;
174(12):
7716 - 7724.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Ruckert, K. Brandt, A. Braun, H.-G. Hoymann, U. Herz, V. Budagian, H. Durkop, H. Renz, and S. Bulfone-Paus
Blocking IL-15 Prevents the Induction of Allergen-Specific T Cells and Allergic Inflammation In Vivo
J. Immunol.,
May 1, 2005;
174(9):
5507 - 5515.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Masuda, Y. Yoshikai, H. Kume, and T. Matsuguchi
The Interaction between GATA Proteins and Activator Protein-1 Promotes the Transcription of IL-13 in Mast Cells
J. Immunol.,
November 1, 2004;
173(9):
5564 - 5573.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Giron-Michel, A. Caignard, M. Fogli, D. Brouty-Boye, D. Briard, M. van Dijk, R. Meazza, S. Ferrini, C. Lebousse-Kerdiles, D. Clay, et al.
Differential STAT3, STAT5, and NF-{kappa}B activation in human hematopoietic progenitors by endogenous interleukin-15: implications in the expression of functional molecules
Blood,
July 1, 2003;
102(1):
109 - 117.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Bulanova, V. Budagian, Z. Orinska, H. Krause, R. Paus, and S. Bulfone-Paus
Mast Cells Express Novel Functional IL-15 Receptor {alpha} Isoforms
J. Immunol.,
May 15, 2003;
170(10):
5045 - 5055.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Giron-Michel, M. Fogli, A. Gaggero, S. Ferrini, A. Caignard, D. Brouty-Boye, S. Baouz, M.-C. Le Bousse-Kerdiles, B. Peault, M. van Dijk, et al.
Detection of a Functional Hybrid Receptor {gamma}c/GM-CSFR{beta} in Human Hematopoietic CD34+ Cells
J. Exp. Med.,
March 17, 2003;
197(6):
763 - 775.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Masuda, Y. Yoshikai, K. Aiba, and T. Matsuguchi
Th2 Cytokine Production from Mast Cells Is Directly Induced by Lipopolysaccharide and Distinctly Regulated by c-Jun N-Terminal Kinase and p38 Pathways
J. Immunol.,
October 1, 2002;
169(7):
3801 - 3810.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Sherman, D. R. Powell, and M. A. Brown
IL-4 Induces the Proteolytic Processing of Mast Cell STAT6
J. Immunol.,
October 1, 2002;
169(7):
3811 - 3818.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Wuttge, P. Eriksson, A. Sirsjo, G. K. Hansson, and S. Stemme
Expression of Interleukin-15 in Mouse and Human Atherosclerotic Lesions
Am. J. Pathol.,
August 1, 2001;
159(2):
417 - 423.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
R. Ishimitsu, H. Nishimura, T. Yajima, T. Watase, H. Kawauchi, and Y. Yoshikai
Overexpression of IL-15 In Vivo Enhances Tc1 Response, Which Inhibits Allergic Inflammation in a Murine Model of Asthma
J. Immunol.,
February 1, 2001;
166(3):
1991 - 2001.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. A. Fehniger and M. A. Caligiuri
Interleukin 15: biology and relevance to human disease
Blood,
January 1, 2001;
97(1):
14 - 32.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Masuda, T. Matsuguchi, K. Yamaki, T. Hayakawa, and Y. Yoshikai
Interleukin-15 Prevents Mouse Mast Cell Apoptosis through STAT6-mediated Bcl-xL Expression
J. Biol. Chem.,
July 6, 2001;
276(28):
26107 - 26113.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|